IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1171-1176

  Hideshima, Hiromasa ^a   Yoshida, Yasuhiro ^a,b   Ikeda, Hiroshi ^a,c   Hide, Maya ^a   Iwasaki, Akinori ^b   Anderson, Kenneth C ^a   Hideshima, Teru ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b FUKUOKA UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bortezomib; Breast cancer; IKK inhibitor; NF B

Indexed keywords

4(2'-AMINOETHYL)AMINO-1,8-DIMETHYLIMIDAZO(1,2-A)QUINOXALINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; I KAPPA B; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; NF-KAPPAB INHIBITOR ALPHA; PYRAZINE DERIVATIVE; QUINOXALINE DERIVATIVE; RELA PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA;

ACTIVE TRANSPORT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; HUMAN; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; IMIDAZOLES; MCF-7 CELLS; PHOSPHORYLATION; PYRAZINES; QUINOXALINES; TRANSCRIPTION FACTOR RELA;

EID: 84894486878     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2273     Document Type: Article

References (32)

1. Jost PJ and Ruland J: Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109: 2700-2707, 2007. (Pubitemid 46482061)
2. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, et al: Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 12: 131-144, 2007. (Pubitemid 47208626)
3. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, et al: Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007. (Pubitemid 47199123)
4. Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K, Raje N, Protopopov A, Munshi NC, Richardson PG, Carrasco RD and Anderson KC: Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 113: 5228-5236, 2009.
5. Baldwin AS Jr: The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996.
6. Beg AA and Baldwin AS Jr: The IκB proteins: multifunctional regulators of Rel NF-κB transcription factors. Genes Dev 7: 2064-2070, 1993.
7. Zandi E, Chen Y and Karin M: Direct phosphorylation of IkappaB by IKKα and IKKβ: discrimination between free and NF-κB-bound substrate. Science 281: 1360-1363, 1998. (Pubitemid 28406830)
8. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E and Karin M: A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 388: 548-554, 1997. (Pubitemid 27339997)
9. Hideshima T, Richardson P, Chauhan D, Palombella V, Elliott P, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001. (Pubitemid 32691956)
10. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99: 14374-14379, 2002. (Pubitemid 35257679)
11. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N and Anderson KC: Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood 101: 1530-1534, 2003. (Pubitemid 36182530)
12. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003. (Pubitemid 36741588)
13. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, et al : Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005. (Pubitemid 41007864)
14. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, et al : Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906-917, 2008.
15. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A and Gradishar WJ: A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 25: 733-737, 2007. (Pubitemid 350223168)
16. Dees EC, Orlowski RZ. Targeting the ubiquitin-proteasome pathway in breast cancer therapy. Future Oncol 2: 121-135, 2006.
17. Schmid P, Kuhnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, Kummel S, et al: A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 19: 871-876, 2008. (Pubitemid 351627300)
18. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D and Orlowski RZ: A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 63: 99-107, 2008.
19. Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ and Baselga J: Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 98: 1500-1507, 2008. (Pubitemid 351652337)
20. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Vigano L, Maur M, Capri G, Maccioni E, Tosi D, et al: Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 44: 1829-1834, 2008.
21. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD and Anderson KC: Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood 114: 1046-1052, 2009.
22. Karin M and Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759, 2005. (Pubitemid 41400849)
23. Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18: 621-663, 2000. (Pubitemid 30365393)
24. Dolcet X, Llobet D, Encinas M, Pallares J, Cabero A, Schoenenberger JA, Comella JX and Matias-Guiu X: Proteasome inhibitors induce death but activate NF-κB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 281: 22118-22130, 2006. (Pubitemid 44181916)
25. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K and Miyamoto S: Bortezomib-resistant nuclear factor-κB activity in multiple myeloma cells. Mol Cancer Res 6: 1356-1364, 2008.
26. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T and Anderson KC: Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63: 6174-6177, 2003. (Pubitemid 37255160)
27. Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, et al: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23: 8766-8776, 2004. (Pubitemid 39593291)
28. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, et al: Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112: 2489-2499, 2008.
29. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. NF-kB as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647, 2002. (Pubitemid 34967682)
30. Garg AK, Hortobagyi GN, Aggarwal BB, Sahin AA and Buchholz TA: Nuclear factor-κB as a predictor of treatment response in breast cancer. Curr Opin Oncol 15: 405-411, 2003. (Pubitemid 38147034)
31. Wu JT and Kral JG: The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 123: 158-169, 2005. (Pubitemid 40094658)
32. Tapia MA, Gonzalez-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, Gascon P, Rojo F, et al: Inhibition of the canonical IKK/NF κB pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 6: 2284-2292, 2007. (Pubitemid 47547707)